Addex Therapeutics (ADXN) Cash from Financing Activities (2019 - 2026)

Addex Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at $83.5 billion in Q1 2026.

• Quarterly Cash from Financing Activities fell 23.34% year-over-year to $83.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.6 billion (up 33.59% YoY) and the FY2025 annual result came in at $1.4 million, up 1097.29% from the prior year.
• Cash from Financing Activities climbed to $83.5 billion in Q1 2026 per ADXN's latest filing, from -$118.4 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $6130.2 billion in Q2 2023 and troughed at -$6000.8 billion in Q4 2023.
• A 5-year average of -$164.6 million and a median of -$175321.9 in 2022 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 3467832720.52% in 2023, down 3422757924.1% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$175321.9 in 2022, then plunged by 3422757924.1% to -$6000.8 billion in 2023, then soared by 97.97% to -$121.7 billion in 2024, then climbed by 2.77% to -$118.4 billion in 2025, then jumped by 170.59% to $83.5 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $83.5 billion, -$118.4 billion, and $109.0 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.